{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:58:56Z","timestamp":1793465936487,"version":"4.5.0"},"reference-count":21,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.5551\/jat.65181","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T17:16:01Z","timestamp":1739466961000},"page":"962-981","source":"Crossref","is-referenced-by-count":11,"title":["A Cost-Effectiveness Analysis for the Combination of Universal Screening at 9-10 Years Old and Reverse Cascade Screening of Relatives for Familial Hypercholesterolemia in Japan"],"prefix":"10.5551","volume":"32","author":[{"given":"Keiji","family":"Matsunaga","sequence":"first","affiliation":[{"name":"Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Rinku General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kanazawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Uda","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Mori","sequence":"additional","affiliation":[{"name":"CRECON Medical Assessment Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"CRECON Medical Assessment Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Inoue","sequence":"additional","affiliation":[{"name":"CRECON Medical Assessment Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Kamae","sequence":"additional","affiliation":[{"name":"Graduate School of Public Policy, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Food and Nutritional Sciences, Chubu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Minamino","sequence":"additional","affiliation":[{"name":"Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Harada-Shiba M, Arai H, Ohmura H, Okazaki H, Sugiyama D, Tada H, Dobashi K, Matsuki K, Minamino T, Yamashita S, Yokote K: Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022. J Atheroscler Thromb, 2023; 30: 558-586","DOI":"10.5551\/jat.CR005"},{"key":"2","unstructured":"2) Japan Atherosclerosis Society (JAS): Guidelines for Prevention of Atherosclerotic Disease 2022 [Internet]. 2022 [accessed 8 May 2023]. Available from: https: \/\/www.j-athero.org\/jp\/jas_gl2022\/"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Watts GF, Gidding SS, Hegele RA, Raal FJ, Sturm AC, Jones LK, Sarkies MN, Al-Rasadi K, Blom DJ, Daccord M, de Ferranti SD, Folco E, Libby P, Mata P, Nawawi HM, Ramaswami U, Ray KK, Stefanutti C, Yamashita S, Pang J, Thompson GR, Santos RD: International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolemia. Nat Rev Cardiol, 2023; 20: 845-869","DOI":"10.1038\/s41569-023-00892-0"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Tada H, Kaneko H, Suzuki Y, Okada A, Takeda N, Fujiu K, Morita H, Ako J, Node K, Takeji Y, Takamura M, Yasunaga H, Komuro I: Familial hypercholesterolemia is related to cardiovascular disease, heart failure and atrial fibrillation. Results from a population-based study. Eur J Clin Invest, 2024; 54: e14119","DOI":"10.1111\/eci.14119"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Bor\u00e9n J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybj\u00e6rg-Hansen A: Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490a","DOI":"10.1093\/eurheartj\/eht273"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Matsunaga K, Mizobuchi A, Ying Fu H, Ishikawa S, Tada H, Kawashiri MA, Yokota I, Sasaki T, Ito S, Kunikata J, Iwase T, Hirao T, Yokoyama K, Hoshikawa Y, Fujisawa T, Dobashi K, Kusaka T, Minamino T: Universal Screening for Familial Hypercholesterolemia in Children in Kagawa, Japan. J Atheroscler Thromb, 2022; 29: 839-849","DOI":"10.5551\/jat.62780"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A: Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolemia in the UK: A cost-utility analysis. Atherosclerosis, 2018; 275: 434-443","DOI":"10.1016\/j.atherosclerosis.2018.05.047"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Jahn B, Santamaria J, Dieplinger H, Binder CJ, Ebenbichler C, Scholl-B\u00fcrgi S, Conrads-Frank A, Rochau U, K\u00fchne F, Stojkov I, Todorovic J, James L, Siebert U: Familial hypercholesterolemia: A systematic review of modeling studies on screening interventions. Atherosclerosis, 2022; 355: 15-29","DOI":"10.1016\/j.atherosclerosis.2022.06.1011"},{"key":"9","unstructured":"9) National Institute for Health and Care Excellence: Inclisiran for treating primary hypercholesterolemia or mixed dyslipidaemia (TA733). [Internet]. 2021 [accessed 8 May 2023]. Available from: https: \/\/www.nice.org.uk\/guidance\/ta733"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N, Kita T: Clinical features of familial hypercholesterolemia in Japan in a database from 1996-1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb, 2004; 11: 146-151","DOI":"10.5551\/jat.11.146"},{"key":"11","unstructured":"11) Cholesterol Treatment Trialists\u2019 Collaboration: Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet, 2019; 393: 407-415"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kelley GA, Kelley KS, Roberts S, Haskell W: Comparison of aerobic exercise, diet or both on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. Clin Nutr, 2012; 31: 156-167","DOI":"10.1016\/j.clnu.2011.11.011"},{"key":"13","unstructured":"13) DeSC Healthcare, Inc. [Internet]. [accessed 11 October 2023]. Available from: https: \/\/desc-hc.co.jp\/"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"15","unstructured":"15) National Institute for Health and Care Excellence: Alirocumab for treating primary hypercholesterolemia and mixed dyslipidaemia (TA393). [Internet]. 2016 [accessed 8 May 2023]. Available from: https: \/\/www.nice.org.uk\/guidance\/ta393"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kodera S, Morita H, Kiyosue A, Ando J, Komuro I: Cost-Effectiveness of Percutaneous Coronary Intervention Compared With Medical Therapy for Ischemic Heart Disease in Japan. Circ J, 2019; 83: 1498-1505","DOI":"10.1253\/circj.CJ-19-0148"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Shiroiwa T, Noto S, Fukuda T: Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings. Value Health, 2021; 24: 1193-1202","DOI":"10.1016\/j.jval.2021.03.010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K: International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ, 2010; 19: 422-437","DOI":"10.1002\/hec.1481"},{"key":"19","unstructured":"19) Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health (C2H),: Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council [Internet]. 2024 [accessed 8 October 2024]. Available from: https: \/\/c2h.niph.go.jp\/tools\/guideline\/index.html"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Marquina C, Morton JI, Lloyd M, Abushanab D, Baek Y, Abebe T, Livori A, Dahal P, Watts GF, Ademi Z: Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolemia: An Updated Systematic Review. Pharmacoeconomics, 2024; 42: 373-392","DOI":"10.1007\/s40273-023-01347-7"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Fu HY, Matsunaga K, Inoue T, Tani R, Funatsuki K, Iwase T, Kondo S, Nishioka K, Ito S, Sasaki T, Yokota I, Hoshikawa Y, Yokoyama K, Fujisawa T, Kawashiri MA, Tada H, Takamura M, Kusaka T, Minamino T: Improved Efficiency of the Clinical Diagnostic Criteria for Familial Hypercholesterolemia in Children: A Comparison of the Japan Atherosclerosis Society Guidelines of 2017 and 2022. J Atheroscler Thromb, 2024; 31: 1048-1057","DOI":"10.5551\/jat.64513"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/8\/32_65181\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:25:03Z","timestamp":1754108703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/8\/32_65181\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65181","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"65181"}}